PMS-Bethanechol

Bethanechol Chloride

Treatment option: Urinary Retention, Reflux

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of PMS-Bethanechol

Property	Description
Active ingredient	Bethanechol Chloride
Form	Tablet (oral), Solution (subcutaneous)
Pharmacological class	Direct-Acting Muscarinic Agonist
Common use	Restoring functional motility and tone
Origin	Synthetic Ester

PMS-Bethanechol is a prescription-only medication containing the single active ingredient Bethanechol Chloride (INN), which is classified pharmacologically as a Direct-Acting Muscarinic Agonist and a Parasympathomimetic Agent. This synthetic compound is a choline carbamate ester that selectively activates muscarinic receptors in the body's involuntary nervous system. The unique chemical feature of a quaternary amine moiety makes the drug resistant to rapid breakdown by the cholinesterase enzyme, providing a more sustained therapeutic effect compared to the body's native neurotransmitter, acetylcholine.

The General Purpose of this Cholinergic Agent

The overall purpose of Bethanechol Chloride is to act as a cholinergic agent to stimulate the parasympathetic nervous system, often known as the "rest and digest" system. By mimicking natural signaling, the drug promotes the necessary contraction of smooth muscles to facilitate bodily functions. It is clinically recognized for its selective action on the smooth muscles of specific organs. The medication functions to stimulate the muscles of the urinary tract and gastrointestinal tract. The key benefit is derived from its ability to enhance the tone and contraction of the detrusor muscle of the urinary bladder and increase motility within the gastrointestinal tract, thus aiding in the completion of vital processes like elimination and digestion when muscle function is sluggish, such as in certain post-operative conditions.

Available Forms and Differentiation

PMS-Bethanechol is a specific trade name for Bethanechol Chloride and is typically supplied as a single-ingredient product (Monoproduct) in two principal pharmaceutical preparations: the oral tablet for routine systemic use, and an aqueous solution intended for the subcutaneous route. While other brands with the same active ingredient exist, all share the same Direct-Acting Muscarinic Agonist properties. These distinct forms allow practitioners to select the most appropriate delivery method to achieve the desired parasympathomimetic response based on clinical necessity.

Regulatory References

Bethanechol: MedlinePlus Drug Information

What side effects are possible with PMS-Bethanechol?

Possible Side Effects and Safety Information

Adverse reactions associated with PMS-Bethanechol (Bethanechol Chloride) are primarily an extension of its pharmacological action as a muscarinic stimulant, affecting multiple organ systems. Official regulatory labeling classifies adverse reactions as rare following oral administration, but they are noted as more common when the drug is administered via subcutaneous injection and are more likely to occur when the dosage is increased.

Systemic Adverse Reactions

The documented effects are grouped into system-organ classes according to official labeling. Gastrointestinal effects include abdominal cramps, nausea, vomiting, diarrhea, and salivation. Cardiovascular effects may include a fall in blood pressure and reflex tachycardia (increased heart rate). Dermatological effects documented are flushing, a sensation of heat, and sweating. Urinary effects include urgency. Headache and general malaise have also been reported.

Serious Reactions and Safety Constraints

Official safety documentation lists several serious adverse reactions, which, though rare, are important to note. These include transient syncope with cardiac arrest and transient complete heart block, particularly associated with larger doses. The drug has the potential to precipitate asthmatic attacks and bronchoconstriction in susceptible individuals.

Safety statements indicate that special caution is required when the drug is co-administered with ganglion blocking compounds, as this combination may result in a critical fall in blood pressure.

Population-Specific Safety Status

Regulatory documents provide explicit safety status for specific populations. The safety and effectiveness of PMS-Bethanechol have not been established in pediatric patients. The medication is categorized as Pregnancy Category C, and its use during pregnancy is reserved for circumstances where it is clearly needed. It is not known whether the drug is secreted in human milk, requiring caution in nursing mothers.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

Overdosage of PMS-Bethanechol (Bethanechol Chloride) results in an exaggeration of its muscarinic effects, typically following the administration of large doses, as documented in official regulatory labeling. Early documented manifestations include salivation, profuse sweating, nausea, and vomiting, often accompanied by abdominal discomfort, colicky pain, and generalized flushing of the skin. Symptoms such as headache and urinary urgency may also be present.

The official profile outlines the potential for severe, life-threatening systemic outcomes. These include critical cardiovascular events such as transient syncope with cardiac arrest, transient complete heart block, and severe toxic cardiovascular responses. Respiratory compromise is also documented, potentially manifesting as dyspnea and severe toxic bronchoconstrictor responses.

When to Seek Immediate Medical Help

Official documentation mandates that the patient must seek emergency medical attention immediately upon suspicion of overdosage. Urgent medical care is specifically required to counteract documented severe toxic cardiovascular or bronchoconstrictor responses.

Official Antidote and Supportive Management

A specific chemical antidote, Atropine Sulfate, is available to manage severe toxicity. The documented adult dose is 0.6 mg, which may be repeated every two hours based on the patient’s clinical response. Supportive management procedures documented in the label may require the use of artificial respiration in severe cases. Antidote dosing (0.01 mg/kg up to 0.4 mg maximum single dose) is also specifically documented for pediatric patients.

Therapeutic Uses of PMS-Bethanechol

What PMS-Bethanechol Treats: Main Uses and Benefits

PMS-Bethanechol is a prescribed medication intended for the management of specific types of urinary retention. This condition is characterized by an inability to completely empty the bladder, which can lead to discomfort and other health concerns. The treatment is primarily designed to help support bladder function, which may assist with the process of urination and the successful emptying of the bladder.

The authorized therapeutic domains for this medication include addressing acute postoperative nonobstructive (functional) urinary retention, postpartum nonobstructive urinary retention, and neurogenic atony of the urinary bladder with retention.

This medication is used to assist patients experiencing difficult or incomplete voiding following a medical event or due to a specific nervous system issue. The indications for use are established based on clinical parameters for urinary tract function.

Quick Fact: Relief for Difficult and Incomplete Voiding

Eligibility and Restrictions for Use

Who Can and Cannot Use PMS-Bethanechol

Eligibility for using PMS-Bethanechol (Bethanechol Chloride) is strictly governed by official regulatory criteria, focusing on absolute contraindications and specific population limitations.

Contraindicated Populations and Conditions

This medicine is contraindicated and must not be used in individuals with a known hypersensitivity to the drug, or those with specific pre-existing conditions as defined by regulatory labeling. These conditions include hyperthyroidism, active bronchial asthma, peptic ulcer disease, epilepsy, or Parkinsonism. Use is also prohibited in patients with certain cardiovascular disorders such as pronounced bradycardia, hypotension, or coronary artery disease.

Furthermore, PMS-Bethanechol is forbidden when there is a mechanical obstruction of either the gastrointestinal (GI) or urinary tract, or if the integrity of the GI or bladder wall is questionable, such as after recent surgery in these areas.

Age and Reproductive Eligibility

Pediatric Use: Safety and effectiveness have not been established in children under 12 years of age.
Pregnancy: The medicine is classified as Category C. Use is restricted and should be administered only if clearly needed.
Lactation: Caution is mandated, requiring a decision to discontinue nursing or discontinue the drug.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory interaction profile for PMS-Bethanechol (Bethanechol Chloride) is primarily defined by high-level pharmacodynamic interactions with substances that affect the involuntary nervous system.

Classification	Documentation Statement
Additive Cholinergic Effects	Co-administration with Cholinesterase Inhibitors (cholinergic drugs) may lead to additive effects, increasing the potential for adverse outcomes [FDA Prescribing Information].
Antagonistic Effects	Anticholinergic Agents are documented to directly counteract the action of bethanechol, potentially neutralizing its therapeutic effect due to muscarinic receptor antagonism.
Cardiovascular Risk	Combining the drug with Ganglionic Blocking Compounds (such as mecamylamine) carries the risk of a critical fall in blood pressure (hypotension) that is often preceded by severe abdominal symptoms [Health Canada Monograph]. The risk of cardiac conduction abnormalities (e.g., bradycardia) may be increased with co-administration of Beta-Blockers.
Food/Timing Constraint	The official labeling includes a timing-based interaction rule with food: The oral dose must be administered on an empty stomach (one hour before or two hours after meals) to minimize the possibility of documented gastrointestinal interaction effects, such as nausea and vomiting [NIH: MedlinePlus].
Other Substances	The risk of adverse effects may be increased when combined with Alcohol or the herbal product Ginkgo biloba.

The documented interaction structure centers on pharmacodynamic reinforcement and antagonism due to the drug's mechanism of action. Official regulatory information does not detail specific metabolic (CYP-mediated) or transporter-based interactions, but does include mandatory administration timing rules to mitigate interaction-related gastrointestinal effects.

Mechanism of Action

Muscarinic Receptor Stimulation: The Core Mechanism

PMS-Bethanechol (bethanechol) acts as a direct-acting muscarinic agonist that engages mechanisms regulating receptor-mediated signaling. It binds selectively to muscarinic acetylcholine receptors, primarily the M3 subtype found on target tissues. This engagement initiates a cascade that modifies early molecular steps, leading to downstream cellular effects.

Enhancement of Smooth Muscle Tone: Physiological Consequence

The compound affects biological systems where specific neurotransmitters dominate, modulating key pathways associated with visceral smooth muscle function. The activation of M3 receptors on the detrusor muscle of the urinary bladder and the smooth muscle of the gastrointestinal (GI) tract leads to a distinct physiological consequence: increased muscle tone and contractility. This physiological adjustment leads to altered contraction patterns, specifically by promoting the contraction of the bladder wall and stimulating GI peristalsis.

Selectivity and Receptor Activation Profile

Unlike the endogenous neurotransmitter acetylcholine, the compound is not hydrolyzed by cholinesterase, resulting in a sustained activation of the receptor. This property is associated with continuous signal transmission. It exhibits minimal effect on nicotinic receptors and, due to its quaternary amine structure, results in localized peripheral effects due to its low penetration of the blood-brain barrier.

Dosage and Administration Information

Administration of PMS-Bethanechol

PMS-Bethanechol is an oral medication typically taken with water. For optimal absorption and to minimize the potential for nausea or vomiting, it is often recommended to take this medication on an empty stomach. This generally means taking the dose either one hour before or two hours after consuming a meal.

Consistency in Use

To maintain a steady level of the medication in the body, it is beneficial to take the doses at the same times each day. Following the schedule provided by a healthcare professional ensures the medication can work effectively for its intended purpose.

Form and Storage

The medication is provided in tablet form. It should be stored at room temperature, away from excessive moisture and direct light. Keeping the tablets in their original container helps protect them from environmental factors that could affect their stability.

Recent Clinical Evidence

Bethanechol has been studied in clinical trials and retrospective analyses for specific approved indications, including the management of urinary retention. The research contributes to the broader evidence landscape but does not determine whether an individual will respond similarly.

Research has explored its use for acute postoperative and postpartum urinary retention. These studies, often short-term Randomized Controlled Trials (RCTs) or retrospective reports, examined objective outcomes such as the volume of Post-Void Residual (PVR) urine and the necessity of catheterization. Findings described patterns where groups observed with the medication were associated with a lower rate of requiring catheterization compared to control groups during the acute recovery setting. The observations reported in these studies apply primarily to this immediate, short-term phase.

Research also examined neurogenic atony, a condition of bladder muscle weakness caused by nerve damage. Studies, including older clinical trials and specialized urodynamic research, monitored changes in bladder pressure and residual urine. Scientific literature frequently notes that observations from clinical series described highly variable or inconsistent patterns depending on the underlying cause of the nerve damage, and certainty remains low for predicting outcomes in certain complex conditions.

The evidence base predominantly provides insight into short-term changes, as follow-up durations were typically limited to the acute event. There is limited information for long-term outcomes or durability of effect. Furthermore, data for certain patient groups, such as pediatric populations or use during pregnancy, remain insufficient, and research quality varies across different indications. The need for more prospective or comparative evidence is consistently noted in the scientific literature.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about PMS-Bethanechol (FAQ)

Q: How long does it usually take for PMS-Bethanechol to start working?

The onset of the medication's effect is described in official documents as differing based on the route of administration. For the oral tablet, official information indicates effects typically begin within 30 to 90 minutes. If administered by subcutaneous injection, effects are seen more rapidly, usually within 5 to 15 minutes.

Q: Can PMS-Bethanechol make you feel dizzy or lightheaded?

Regulatory information lists dizziness as a possible side effect of PMS-Bethanechol. Other documented effects related to this sensation include a fall in blood pressure and a general feeling of illness known as malaise.

Q: Are there any long-term side effects associated with PMS-Bethanechol use?

The medication is frequently used for short-term acute conditions, such as postoperative urinary retention. Because of this, official information primarily documents the profile of effects observed during short-term use. Studies have noted that there is limited information available regarding long-term outcomes or the durability of effect.

Q: Does PMS-Bethanechol interact with blood pressure medications?

Official sources describe a potential for interaction with certain classes of blood pressure medication, specifically Beta-Blockers and Ganglionic Blocking Compounds. The combination is noted to carry a risk of a fall in blood pressure.

Q: Does the drug interact with any common supplements like vitamins or herbal products?

Official regulatory labeling advises caution regarding interactions with vitamins and herbal products, in addition to prescription and over-the-counter medicines. The herbal product Ginkgo biloba is specifically noted in regulatory documents to increase the risk of adverse effects.

Q: Can teenagers or younger adults be prescribed PMS-Bethanechol?

Official information states that the safety and effectiveness of the medication have not been established in pediatric patients under 12 years of age. Prescribing information for individuals 12 years and older typically refers to the adult dosing profile.

Q: Is bethanechol different from oxybutynin?

Yes, these two medications belong to opposing pharmacological classes. Bethanechol acts as a cholinergic agonist, meaning it stimulates certain nerve receptors. Oxybutynin, conversely, is an anticholinergic agent, and regulatory documents state that this class of drugs directly counteracts the action of bethanechol.

Q: What is the typical duration of treatment with PMS-Bethanechol?

The treatment length depends on the specific condition being addressed. For acute issues like post-operative urinary retention, short-term use, often 3–7 days, is typically sufficient. For chronic conditions, ongoing therapy with regular medical evaluation may be required.

Q: Is there recent research on new uses for bethanechol?

Regulatory-affiliated sources, such as clinical trial registries, confirm that the drug is being studied for investigational uses not yet listed on the official label. Examples include research into its potential effects in conditions like Tracheobronchomalacia and specific uses in certain surgical settings.

Q: Does PMS-Bethanechol treat the underlying cause or just the symptoms?

The medication works as a direct-acting muscarinic agonist that stimulates the involuntary nervous system to restore muscle tone and motility in the bladder and GI tract. This is classified as a physiological effect directed at correcting muscle function for the approved conditions.

Q: What happens if I miss a scheduled dose?

Official regulatory sources advise that if a dose is missed, it can be taken as soon as it is remembered. However, if it is near the time for the next scheduled dose, the missed dose is advised to be skipped to prevent a double dose.

Q: Can I take PMS-Bethanechol with over-the-counter pain relievers?

Official product information indicates that the use of all over-the-counter medicines, including pain relievers, requires discussion with a healthcare professional.

Q: Is PMS-Bethanechol suitable for elderly patients?

Clinical information suggests that use in older patients requires caution. This is due to potentially limited effectiveness in some cases and an increased possibility of experiencing adverse effects such as flushing, vomiting, and diarrhea.

Q: Where can I find official information about the research evidence for this drug?

Official information about research evidence is typically available on government-run websites and intergovernmental bodies. This includes the NIH (via PubMed or MedlinePlus), ClinicalTrials.gov, and official drug labeling documents from agencies like the FDA or EMA.

How should PMS-Bethanechol be stored and disposed of?

Storage and Disposal of PMS-Bethanechol

Bethanechol chloride tablets must be stored at Controlled Room Temperature, specifically between 20° to 25°C (68° to 77°F), with permitted temperature excursions up to 30°C (86°F).

Mandatory Storage Requirements

Environment: The medicine must be kept away from excess heat, moisture, and direct light and kept from freezing.
Container: The tablets must be stored and dispensed in a tight, light-resistant container with a child-resistant closure, and packaging integrity must be maintained (e.g., do not use if blister is torn).
Child Safety: It is mandatory to keep this medicine out of the reach of children.

Official Disposal

Do not dispose of bethanechol tablets in wastewater (e.g., down the sink or toilet). For unused or expired medicine, patients should consult a pharmacist or use a designated community drug take-back program as the preferred method for disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Canada

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z